Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Long‑term safety and tolerability of oral nizubaglustat in patients with rare lysosomal disorders who have completed a prior study

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

The trial involves people with rare lysosomal disorders such as GM1 gangliosidosis, GM2 gangliosidosis, Niemann-Pick disease type C, and Gaucher disease type 3. These conditions affect the cell’s recycling system, causing harmful material to build up. Participants will receive the oral medication nizubaglustat (code name AZ-3102) in the form of an orodispersible tablet, which dissolves in the mouth.

The study aims to assess the long‑term safety and tolerability of continued daily use of the medication. Safety will be monitored by checking for side effects, changes in vital signs such as blood pressure and heart rate, and routine blood tests that look at blood cells, clotting, and chemistry. Blood samples will also be used to measure specific markers that reflect disease activity for each condition.

After giving informed consent, participants will take the study drug each day for an extended period, with regular clinic visits where health status and laboratory results are reviewed. The schedule includes periodic assessments over many months to observe how the body responds over time. No additional experimental procedures are required beyond the standard monitoring visits.

The research process

The trial runs in 8 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Informed Consent

    You will meet with study staff to receive information about the trial and sign a consent form indicating that you agree to participate.

    The study is open‑label, meaning you and the investigators will know that you are receiving nizubaglustat.

  2. Step 2

    Baseline Assessments

    Before starting the medication, you will undergo a series of checks that include measuring your vital signs (such as blood pressure and heart rate) and providing blood samples for laboratory safety tests.

    These tests help establish your health status at the beginning of the trial and will be used for later comparison.

  3. Step 3

    Start of Daily Medication

    You will begin taking nizubaglustat as an oral orodispersible tablet containing 9 mg of the active substance.

    The tablet is taken once each day, preferably at the same time each day, and can be dissolved in the mouth before swallowing.

  4. Step 4

    Ongoing Daily Dosing

    You will continue the daily dose of 9 mg for the entire duration of the study, which may extend for several years.

    If you miss a dose, you should follow the instructions provided by the study team on how to handle missed doses.

  5. Step 5

    Regular Study Visits

    You will attend scheduled visits, typically every three months, during which the study team will check your vital signs, review any adverse events (side effects), and collect blood samples.

    These visits allow the investigators to monitor the long‑term safety and tolerability of the medication.

  6. Step 6

    Safety Monitoring and Laboratory Tests

    At each visit, laboratory tests will assess blood counts, clotting ability, and chemistry values to detect any changes that might be related to the medication.

    Specific blood markers related to your condition—such as plasma lyso‑GM1 for GM1 gangliosidosis, plasma lyso‑GM2 for GM2 gangliosidosis, plasma PPCS for Niemann‑Pick disease type C, and glucosylsphingosine for Gaucher disease type 3—may also be measured.

  7. Step 7

    Reporting of Adverse Events

    You are asked to inform the study team of any new symptoms, discomfort, or health changes you experience at any time, even between scheduled visits.

    These reports help determine the incidence and severity of treatment‑emergent adverse events.

  8. Step 8

    Continuation Until Study Completion

    You will remain in the trial and continue daily dosing until the study ends, unless a serious safety concern arises or you choose to stop participation.

    The estimated end date for the overall study is April 1, 2030.

Who can join the trial?

9 criteria

  • Must have already taken part in a previous trial of nizubaglustat and want to continue taking the medicine in this open‑label extension study.
  • The trial doctor (Principal Investigator) must agree that joining the study is appropriate and likely to be helpful for you.
  • You must be willing and able to attend study visits and complete the required assessments.
  • You (or your parent or legal guardian) must read, understand, and sign the informed consent form; if you cannot give consent yourself, your parent/guardian will sign and you will also give your assent.
  • Women who could become pregnant (post‑menarche and not yet menopausal) can join if they either stay sexually inactive (no sexual activity) for 14 days before the first dose and continue until 28 days after the last dose, or use a highly effective birth‑control method (less than 1 % chance of failure) such as an intrauterine device, a partner’s vasectomy (sperm‑cutting surgery) done at least 6 months ago, combined hormonal contraception (pills, patch, or ring that contain estrogen and progestogen and prevent ovulation), progestogen‑only hormonal methods (pills, injection, implant, or hormonal IUD), or a hormonal IUD.
  • Women who cannot become pregnant can join if they have had a permanent sterilization procedure (e.g., hysteroscopic sterilization, removal of both fallopian tubes, removal of the uterus, or removal of both ovaries) at least 6 months ago, or are post‑menopausal (no periods for at least 1 year and a blood test showing high follicle‑stimulating hormone (FSH) levels), or are pre‑menarchal (have not started menstruating) and agree to stay sexually inactive or use one of the birth‑control methods listed above.
  • Men who have not had a vasectomy must agree to use a condom that contains spermicide or to avoid sexual activity for 90 days after the last dose; their female partner must also agree to follow this rule.
  • Men who had a vasectomy at least 6 months ago must agree to use a condom during any sexual activity; men with a vasectomy done less than 6 months ago must follow the same restrictions as men without a vasectomy.
  • All male participants must not donate sperm from the start of treatment until 90 days after the last dose; female participants must not donate eggs during the same period.

Who cannot join the trial?

4 criteria

  • Having a positive pregnancy test (a blood test that shows you are pregnant) if you could become pregnant.
  • Having any health problem that the Principal Investigator (the doctor in charge of the study) thinks would make it unsafe to join, such as a severe infection (a serious sickness caused by germs) or severe cognitive impairment (significant trouble with thinking, memory, or understanding).
  • Using other medicines that work in the same way as the study drug, called GCS or NLGase inhibitors (drugs that block certain enzymes), for example miglustat or venglustat.
  • Being enrolled in another interventional trial (a study that tests a new treatment) or a non‑interventional study (a study that only observes patients) or taking part in an Early Access Program (getting a drug before it is fully approved).
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Nizubaglustat is an experimental oral medication that comes in a tablet that dissolves in the mouth. It is being studied in people with rare lysosomal disorders, which are conditions where the body’s cells cannot break down certain substances properly. In this trial, participants who have already taken the drug in earlier studies continue to take it each day to help researchers learn how safe it is over a longer period and how well people can tolerate it. The drug is considered an orphan drug, meaning it is intended for a very small number of patients with these rare diseases.

What is already known about the treatment

Nizubaglustat - Nizubaglustat is taken as a 9 mg oral orodispersible tablet that dissolves in the mouth and is swallowed each day. It is an investigational drug with orphan‑drug status and is not yet approved for general use, being studied in several clinical trials for rare lysosomal disorders. The medicine is intended for conditions such as GM1 and GM2 gangliosidosis, Niemann‑Pick disease type C, and Gaucher disease type 3, which involve harmful buildup of certain fats in cells. It works by blocking a key enzyme that makes these fats, lowering their amount in the body, and is classified as a substrate‑reduction therapy small‑molecule drug.

Investigated diseases

  • GM1 gangliosidosis

    A rare inherited disorder in which the fatty molecule GM1 builds up inside cells, especially in the brain and other tissues. This accumulation leads to gradual loss of motor skills, coordination problems, and enlargement of the liver and spleen. Symptoms typically appear in infancy or early childhood and become more pronounced over time.

  • GM2 gangliosidosis

    A group of rare genetic conditions, including Tay‑Sachs and Sandhoff disease, where the fatty substance GM2 accumulates in nerve cells. The buildup causes a steady decline in movement abilities, vision, and mental function. The disease usually starts in infancy or early childhood and worsens progressively.

  • Niemann-Pick disease type C

    A rare genetic disorder that impairs the transport of cholesterol and other lipids, leading to their storage in the brain, liver, and spleen. Over time this causes worsening balance problems, difficulty with movement, and a gradual decline in thinking abilities. Symptoms can begin in childhood or later, and they slowly become more severe.

  • Gaucher disease type 3

    The chronic form of Gaucher disease in which fatty substances accumulate in the spleen, liver, bone, and sometimes the brain. It leads to gradual organ enlargement, bone pain, and increasing difficulty with movement. Signs usually emerge in childhood or adolescence and progress slowly over many years.

Trial detailsLast updated 19 Nov 2026
Age18+ yearsPhasePhase IIITrial ID2026-527156-12-00Protocol codeAZA-001-302-MIEstimated enrolment177 patientsSponsorAzafaros B.V.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.